Document is current

Article History

Received: 4 March 2022

Revised: 21 June 2022

Accepted: 5 July 2022

First Online: 1 August 2022

Declarations

:

: Funding sources for this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

: Parental/guardian consent was required for participation.

: All authors declare no real or perceived conflicts of interest that could affect the study design, collection, analyses, and interpretation of data, writing of the report, or the decision to submit for publication. For full disclosure, we provide here an additional list of authors’ commitments and funding sources that are not directly related to this study:Dr. Askenazi is a consultant for Baxter, Nuwellis. Medtronic, BioPorto, and SeaStar. His institution receives external education and research funding not related to this project from Baxter, Nuwellis, Medtronic, Seastar, and Bioporto. He has patents pending for inventions in the neonatal nephology field. He is Chief Scientific Officer of Zorro-Flow Inc.Dr. Goldstein reports personal fees from and a position and as a consultant to Nuwellis, Renibus, ExThera, Reata, and Medtronic Inc. Dr. Goldstein receives grant funding from and serves as a consultant and on a Speaker’s Bureau for Baxter Healthcare, Inc. Dr. Goldstein receives grant funding and serves as a consultant for BioPorto, Inc. Dr. Goldstein serves on a Speaker’s Bureau for Fresenius Medical Corporation. Dr. Juul receives grant funding from NINDS and NICHD for studies not related to this project. Dr. Heagerty and Mr. Schmicker receive grant funding from NIH and PCORI for studies not related to this project.